Palatin Technologies, Inc. (PTN) News
Filter PTN News Items
PTN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PTN News Highlights
- For PTN, its 30 day story count is now at 2.
- Over the past 2 days, the trend for PTN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- TR are the most mentioned tickers in articles about PTN.
Latest PTN News From Around the Web
Below are the latest news stories about PALATIN TECHNOLOGIES INC that investors may wish to consider to help them evaluate PTN as an investment opportunity.
Analysts Say 3 Stocks Have a Combined Upside of 3000%These high-risk, high-reward bets could be at an inflection point before their growth takes off next year. |
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 MillionPalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the sale of Vyleesi® to Cosette Pharmaceuticals, a US-based, speciality pharmaceutical company, for up to $171 million, consisting of an upfront purchase price of $12 million plus contingent, sales-based milestone payments of up to $159 million. Vyleesi is the first and only as-needed tr |
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE AmericanPalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") approving Palatin's plan (the "Plan") to come into compliance with the Exchange's continued listing standards under Section 1003(a)(i) and (ii) of the NYSE American Company Guide. Section 1003(a)(i) requires a list |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to dive into the biggest pre-market stock movers for Friday morning as we check out the winners and losers today! |
Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call TranscriptPalatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript November 14, 2023 Operator: Greetings. Welcome to Palatin’s First Quarter Fiscal Year 2024 Operating Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. Before […] |
Q1 2024 Palatin Technologies Inc Earnings CallQ1 2024 Palatin Technologies Inc Earnings Call |
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdatePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal first quarter ended September 30, 2023, and provided a corporate update. |
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue EstimatesKronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -5.88% and 63.32%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before the open of the U.S. financial markets. |
Palatin Announces Closing of $5 Million Registered Direct OfferingPalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 2,358,491 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $2.12 per share of common stock (or common stock equivalents in lieu thereof). Pal |